NASDAQ · Health care

Biofrontera Inc. (BFRI)

Biofrontera Inc. brought in $46.2M of revenue over the twelve months to June 30, 2026, up 17.8% from a year earlier. It posted a net loss of $6.4M. In fiscal 2025 capital spending exceeded operating cash flow by $13.4M. At June 30, 2026 it held $4.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Watch BFRI in 60 seconds

Price

$0.93

+0.70% on the day · November 11, 2026

52-week range $0.56 to $1.66

Market cap

$13.9M

Revenue (last 12 months)

$46.2M

+17.8% year on year

Net margin

-13.8%

Key facts about Biofrontera Inc.

Net worth: Biofrontera Inc. has a market value (market cap) of $13.9M at the latest share price, and shareholders' equity of $6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was $41.7M (+11.7% year on year), with a net loss of $10.5M. Over the 12 months to June 30, 2026: revenue $46.2M, net loss $6.4M.
Cash flow: In fiscal 2025 operations used $13.4M of cash.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
Next earnings report: Biofrontera Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What Biofrontera Inc. does

Biofrontera Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BFRI.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$41.7M	-$11.3M	-$10.5M	-$1.04	-$13.4M
2024	$37.3M	-$17.2M	-$17.8M	-$3.22	-$10.3M
2023	$34.1M	-$22.7M	-$20.1M	-$13.02	-$24.9M
2022	$28.7M	-$18.6M	-$640K	-$0.61	-$16.2M
2021	$24.1M	-$25.2M	-$37.7M	-$4.28	n/a
2021	$18.8M	-$9.6M	-$11M	-$479.48	n/a

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Next report expected around November 12, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 13, 2025. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Where BFRI ranks in Health care

Revenue$41.7M

#412 of 751 in Health care · Bottom 45%

Revenue growth+11.7%

#263 of 532 in Health care · Top 49%

Net margin-25.3%

#340 of 544 in Health care · Bottom 38%

Free cash flow margin-32.0%

#350 of 490 in Health care · Bottom 29%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Biofrontera Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 14, 2026
Other event 8-K
August 13, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue rose 33% to $12M versus the same quarter last year; diluted EPS -$0.05 versus -$0.57.
August 13, 2026
Quarterly results 8-K
August 12, 2026
Passive stake changed SCHEDULE 13G/A
July 22, 2026
Employee stock plan registration S-8
July 22, 2026
Annual report (amended) 10-K/A · period to December 31, 2025Revenue rose 12% to $41.7M versus the prior year; diluted EPS -$1.04 versus -$3.22.
June 17, 2026
Shareholder vote results 8-K
May 14, 2026
Quarterly report 10-Q · period to March 31, 2026Revenue rose 17% to $10.1M versus the same quarter last year; diluted EPS -$0.41 versus -$0.47.
May 14, 2026
Quarterly results 8-K
April 30, 2026
Proxy statement DEF 14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 29, 2026. Insider transactions on SEC

Insider trades

What the people running Biofrontera Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
July 28, 2026	Leffler Eugene FrederickChief Financial Officer	Exercised options	31,250	-	-	Form 4
July 28, 2026	Luebbert HermannCEO & Chairman, Director	Exercised options	62,500	-	-	Form 4
March 5, 2026	Leffler Eugene FrederickChief Financial Officer	Exercised options	87,500	-	-	Form 4
March 5, 2026	Luebbert HermannCEO & Chairman, Director	Exercised options	137,500	-	-	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns BFRI

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Deutsche Balaton Aktiengesellschaft13D, may seek influence with 7 related filers	19.99%	2,552,230	September 19, 2025
Laurence W. Lytton13G, passive	9.99%	554,884	November 14, 2024
Rosalind Advisors, Inc.13G, passive with 3 related filers	9.9%	16,801,629	August 12, 2026
Orin Hirschman13G, passive with 1 related filers	7.9%	915,210	January 28, 2026

Latest filings below 5%: Lytton Laurence W 3.5% (May 15, 2025); Armistice Capital, LLC 4.99% (November 14, 2024); Nabil Saad 0% (November 13, 2024).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 558,961 shares in total, about $522.1K at the last price.

Holder	Shares	As of
Luebbert HermannCEO & Chairman, Director	352,711	July 28, 2026
Leffler Eugene FrederickChief Financial Officer	206,250	July 28, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about BFRI

What does Biofrontera Inc. do?

Biofrontera Inc. is a company in the Health care sector, listed on NASDAQ as BFRI. Its shares trade on NASDAQ under the ticker BFRI.

What is Biofrontera Inc.'s net worth?

Biofrontera Inc. has a market value (market cap) of $13.9M at the latest share price, and shareholders' equity of $6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Biofrontera Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $6.4M on revenue of $46.2M.

How much revenue does Biofrontera Inc. make?

Over the twelve months to June 30, 2026 Biofrontera Inc. reported revenue of $46.2M. That is 17.8% more than a year earlier.

When did Biofrontera Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 14, 2026.

When is Biofrontera Inc.'s next earnings report?

Biofrontera Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

CMMB

Chemomab Therapeutics Ltd.

PBM

Psyence Biomedical Ltd.

AKTX

Akari Therapeutics Plc

ADIL

Adial Pharmaceuticals, Inc.

SKYE

Skye Bioscience, Inc.

GTBP

GT Biopharma, Inc.

Compare BFRI with

Compare BFRI with any company

Follow BFRI

Get an email when Biofrontera Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values Biofrontera Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.